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It has been shown previously that female mice homozygous for an alpha-fetoprotein (AFP) null allele are
sterile as a result of anovulation, probably due to a defect in the hypothalamic-pituitary axis. Here we show that
these female mice exhibit specific anomalies in the expression of numerous genes in the pituitary, including
genes involved in the gonadotropin-releasing hormone pathway, which are underexpressed. In the hypothal-
amus, the gonadotropin-releasing hormone gene, Gnrh1, was also found to be down-regulated. However,
pituitary gene expression could be normalized and fertility could be rescued by blocking prenatal estrogen
synthesis using an aromatase inhibitor. These results show that AFP protects the developing female brain from
the adverse effects of prenatal estrogen exposure and clarify a long-running debate on the role of this fetal
protein in brain sexual differentiation.
The alpha-fetoprotein (AFP) gene is a member of the albu-
min gene family and encodes a serum glycoprotein with an
oncofetal pattern of expression. AFP is produced in high con-
centrations during embryonic life by the hepatocytes and the
visceral endoderm of the yolk sac and to a lesser extent by the
developing gastrointestinal tract and kidney (2, 26, 39). Its
synthesis decreases dramatically shortly after birth to reach
trace amounts a few weeks later but can be restored during life
when liver pathologies or some types of tumors develop (hep-
atitis, cirrhosis, hepatoma, teratocarcinoma, and some pancre-
atic and renal tumors) (1, 11, 26, 27, 31, 39).
The exact function of AFP has been the subject of a long-
running debate. One important feature of AFP is its capacity
to bind estrogens, but not androgens, at its C-terminal extrem-
ity with a Ka of 10
9 M1 (33, 35, 43), indicating that it can act
as an estrogen carrier in the blood. Although human AFP has
not been demonstrated to bind estrogens, human AFP pep-
tides do so and human AFP possesses an antiestrogenic activity
(7, 44). Human AFP could thus be involved in antiestrogenic
effects, just like rodent AFP. Because perinatal exposure to
estrogens in rodent females results in anovulatory sterility as-
sociated with altered gonadotropin production (16, 23, 29), it is
classically assumed that the function of AFP is to sequester
circulating estrogens and, by so doing, to protect the develop-
ing female brain from their effects (for a review, see reference
32). Alternatively, because AFP is found inside neurons with-
out being produced locally, it has been suggested that AFP has
more than a passive neuroprotective role and specifically de-
livers estrogens into certain brain cells in order to ensure
correct female brain differentiation (18, 41).
Afp gene knockout (AFP KO) mice have been generated by
Gabant and coworkers (21). The mice homozygous for the
targeted allele are viable and develop normally, but females
are sterile due to anovulation. Reciprocal transfer experiments
with ovarian tissue have demonstrated that the ovaries are
functional but lack an adequate signal from the hypothalamic-
pituitary axis to execute ovulation. To determine which path-
ways of the hypothalamic-pituitary-gonadal axis are altered in
adult female AFP KO mice, we compared the gene expression
profiles in such females and their normal counterparts by mi-
croarray analysis. Furthermore, these knockout animals al-
lowed us to determine whether AFP has only a neuroprotec-
tive role (passive estrogen carrier) or not. We reasoned that if
AFP was essentially a passive estrogen carrier, the fertility of
the AFP KO females should be restored if their embryonic
development could take place in the absence of estrogens.
Estrogen-free pregnancy can be achieved by treating pregnant
females with an aromatase inhibitor (8). We have thus deter-
mined whether the fertility of AFP KO females that developed
in an estrogen-free environment was rescued, as well as
whether their gene expression profiles in the hypothalamic-
pituitary-gonadal axis were normalized.
MATERIALS AND METHODS
Microarray study. (i) Animals. AFP KO mice have been described previously
(21). The CD1 animals used in the microarray analysis were bearing the
Afptm2Ibmm allele (knockout 2, described in reference 21) and were from the fifth
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backcross generation. Mice were housed under a 12-h light/dark cycle (lights off
at 6:30 p.m.). Food and water (Scientific Animal Food and Engineering, Augy,
France) were available ad libitum. Animals were killed by cervical dislocation
between the ages of 4 and 5 months. Females were in the metoestrus II/dioestrus
phases of the estrus cycle as established by vaginal smears, according to our
previous observation that AFP KO females remain in these phases (21). The
pituitaries were dissected in one piece while a 4-mm3 side piece was cut around
the pituitary stalk in the brain, permitting dissection of a zone containing the
hypothalamus. Tissues were immediately processed after dissection by disruption
in a Dounce homogenizer in the presence of TRIzol reagent (Life Technologies,
Inc., Carlsbad, CA). Total RNA was further extracted according to the TRIzol
manufacturer’s instructions and resuspended in RNA storage solution (Ambion
Inc., TX).
(ii) RNA preparation and Affymetrix GeneChip hybridization. The quality of
the RNAs was checked with an Agilent 2100 bioanalyzer (Agilent Technologies,
Palo Alto, CA). All the RNAs used in the experiment met the quality criteria
defined by Agilent. Genes expressed in each sample were analyzed on a high-
density oligonucleotide microarray (MOE-430A; Affymetrix, Santa Clara, CA)
containing 22,690 transcripts. Target preparation and microarray processing pro-
cedures were performed as described in the Affymetrix GeneChip Expression
Analysis Manual. Briefly, 3 g of total RNA was used to synthesize double-
stranded cDNA with SuperScript II reverse transcriptase (Life Technologies,
Inc., Rockville, MD) and a T7-(dT)24 primer (Proligo, Paris, France). Then,
biotinylated cRNA was synthesized from the double-stranded cDNA with the
RNA transcript labeling kit (Enzo Life Sciences, Farmingdale, NY) and was
purified and fragmented. The fragmented cRNA was hybridized into the oligo-
nucleotide microarray, which was washed and stained with streptavidin-phyco-
erythrin. Scanning was performed with an Agilent microarray scanner.
(iii) Data analysis. All the “dat” files (corresponding to the scan image) and
the “rpt” files (corresponding to each GeneChip) were first checked for the
control of hybridization defined by the Affymetrix GeneChip manual (uniformity
of the signal, good position of the grid, scale factor, background, percentage of
presence, and presence of housekeeping genes and spike control). All experi-
ments were also analyzed with the “deg” algorithm associated with Bioconductor
1.3 software (http://www.bioconductor.org/). This algorithm analyzes the quality
of the mRNA by comparing the signal intensities in the 5 and 3 ends of the
mRNA, which should be similar if no RNA degradation has occurred. All quality
controls were positive and are available in Table S1 in the supplemental material.
We also conducted an analysis using robust microarray analysis (RMA), which
first calculates the probe-specific correction of the perfect-match probes using a
model based on observed intensity being the sum of signal and noise and then
normalizes the perfect-match probes by quantile normalization. The expression
measure was calculated using a median polish (24, 25). The “Cel” files of each
experiment were collected with Bioconductor 1.3 software and treated according
to the RMA package (we used quantile normalization). All data were then
collected by BRB 3.1 software, developed by Richard Simon and Amy Peng Lam
(http://linus.nci.nih.gov/BRB-ArrayTools.html). A list of genes was generated
using the Class Comparison Tool associated with BRB 3.1. Because of the small
sample size, a randomized-variance t test was used with a threshold level of
significance (P) of 0.05. In addition, an FDR (“false discovery rate”) correction
procedure was applied using a P value of 0.05 (5, 6).
(iv) Real-time PCR analysis. Results obtained by the microarray technology
were confirmed with reverse transcription and quantitative PCR amplification
(quantitative RT-PCR) technology. Results from the pituitary were confirmed
with 7900HT microfluidic card (Applied Biosystems, Foster City, CA) technol-
ogy. For each group of animals (wild-type [WT] and knockout females), we used
two mRNA samples that were previously analyzed with microarray technology
and an additional one not analyzed before. RNA (1 g) from each animal was
retrotranscribed with the high capacity cDNA archive kit (Applied Biosystems)
in a total volume of 10 l. Then, 1 l of the RT product (100 ng cDNA) was
loaded into each well of the 7900HT microfluidic card (Applied Biosystems) for
quantitative PCR amplification with universal PCR master mix (Applied Biosys-
tems). Data were analyzed by the relative quantification software available on the
machine. The housekeeping gene Hprt (hypoxanthine guanine phosphoribosyl
transferase) was used as a reference gene for normalization. In the case of the
Gnrh1 gene (gonadotropin-releasing hormone), the differential expression be-
tween normal and knockout females (n  7 [each genotype]) was tested on
the 7300 real-time PCR system (Applied Biosystems) with the absolute
quantification software. Total RNA (1 g) was retrotranscribed with the high
capacity cDNA archive kit (Applied Biosystems), and 100 ng of cDNA was
brought in the PCR mixture. The housekeeping gene Hprt was used as
reference gene for normalization. PCR was performed with qPCR MasterMix
for SYBR Green I (Eurogentec, Seraing, Belgium).
Aromatase inhibitor treatment. Females heterozygous for the Afptm2Ibmm al-
lele (CD1 strain, eighth backcross level) were mated with Afptm2Ibmm homozy-
gous males and housed under the conditions described above. They then re-
ceived a daily subcutaneous injection in the neck of 4 mg of the aromatase
inhibitor ATD (1,4,6-androstatrien-3,17-dione; Steraloids, Newport, Rhode
Island) dissolved in propylene glycol, from day 13.5 of gestation (day 0.5 was
defined as the day of vaginal plug detection) until the end of gestation. Controls
were injected with propylene glycol only. Pups were born naturally or retrieved
by cesarean operation on embryonic day 20.5. Blood from the mothers was taken
from the heart, and estradiol levels were measured by classical radioimmunoas-
say. Fertility of female pups was tested at the age of 2 to 3 months. In parallel,
sisters of the female pups tested were dissected at the age of 3 months, and total
RNA was extracted from the pituitary and the hypothalamus as described above.
cDNA was obtained using the TaqMan reverse transcription reagent kit (Ap-
plied Biosystems), and real-time PCR was performed on the 7300 real-time PCR
system (Applied Biosystems) with the Platinum Quantitative PCR SuperMix-
UDG kit (Invitrogen) and TaqMan Gene Expression Assays (Applied Biosys-
tems) for pituitary genes except for Egr1. The Gnrh1 and Egr1 transcripts were
quantified with the same machine and software but with the Platinum SYBR
Green qPCR SuperMix-UDG kit (Invitrogen, Carlsbad, California) for PCR.
Statistical testing for pairwise comparison between groups was made with the t
test (  0.05) or with the Mann-Whitney rank sum test.
RESULTS
Gene expression profile in the AFP KO female hypothalamic-
pituitary axis. Total RNA from the pituitary of phenotypically
normal WT mice and AFP KO mice (n  3 [each group]) was
analyzed by Affymetrix microarray technology on mouse ex-
pression set 430A. We first compared the WT females to the
AFP KO females. In order to reduce the background gener-
ated by genes whose expression levels were very close to the
median expression level, we first filtered data by choosing the
genes showing a variance of the log ratio significantly different
from the median of all the variances (P  0.01). Using this
step, a total of 2,676 probe sets were selected. We then used a
nonpaired randomized-variance t test with a P value of 0.05
(because of the small size of the samples) (4). This test gen-
erated a list of 1,392 differently expressed probe sets associated
with the AFP KO phenotype. As described in Materials and
Methods, an FDR procedure (5, 6) was applied to correct the
P value for multiple comparisons, and 929 probe sets showing
differential expression were validated with a P value of 0.05.
Complete results are summarized in Table S2 in the supple-
mental material. These genes define the AFP KO female sig-
nature. The extreme values were 0.203 for the lower range (Fos
[FBJ osteosarcoma oncogene]) and 4.464 for the upper range
(epidermal arachidonate lipoxygenase). In this list, 47 probe
sets corresponding to 39 different genes (because of the redun-
dancy of probe sets) showed a minimum twofold change. They
are listed in Table 1. We also compared the WT males to the
AFP KO males. No anomalies were detected in the AFP KO
males; thus, the male pituitaries were not further analyzed.
The microarray results obtained for female animals were
then validated by quantitative RT-PCR experiments. Among
the 929 genes showing differential expression (and listed in
Table S2 in the supplemental material), 34 genes were selected
according to two criteria—their biological relevance in fertility
pathways (GnRH receptor pathway, lactation) or in neuronal
activity and their differences in expression level—to cover a
wide range of up- and down-regulation in the AFP KO female
pituitaries. The results are shown in Table 1 (12 genes showing
a minimum twofold change in the microarray analysis and 22
other genes among the 34 selected genes). A total of 33 of the
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TABLE 1. Selected genes differentially expressed in female AFP KO pituitaries
Affymetrix probe set Unigene no. Gene symbol
Fold geometric mean change as
established by a:
Microarray RT-PCR
Genes differentially expressed by a factor of 2
(microarray analysis)
1423100_at Mm.246513 Fos 0.203 0.462
1417025_at Mm.22564 H2-Eb1 0.277
1450407_a_at Mm.269088 Anp32a 0.278
1418188_a_at Mm.358667 Ramp2 0.281
1421665_a_at Mm.26791 Gnrhr 0.285 0.588
1416236_a_at Mm.33240 Eva1 0.310 0.535
1424609_a_at Mm.182434 Fstl1 0.317
1448107_x_at Mm.142722 Klk6 0.327
1424607_a_at Mm.181959 Egr1 0.348 0.628
1456341_a_at Mm.291595 Bteb1 0.351
1427104_at Mm.87487 Zfp612 0.378
1438676_at Mm.275893 Mpa21 0.391
1422809_at Mm.309296 Rims2 0.400 0.552
1454607_s_at Mm.289936 Psat1 0.405
1455988_a_at Mm.153159 Cct6a 0.407
1448830_at Mm.239041 Dusp1 0.409
1417513_at Mm.35796 Evi5 0.413
1418908_at Mm.5121 Pam 0.423
1423804_a_at Mm.29847 Idi1 0.426
1437082_at Mm.46044 Akap9 0.442
1423619_at Mm.3903 Rasd1 0.449
1456175_a_at Mm.261735 Copb2 0.454
1416131_s_at Mm.260647 C920006C10Rik 0.462
1434113_a_at Mm.252772 Xpmc2h 0.472
1429296_at Mm.74596 Rab10 0.475
1426956_a_at Mm.215389 Trp53bp1 0.476
1452377_at Mm.2389 Mll 0.478
1434578_x_at Mm.297440 Ran 0.485
1433446_at Mm.61526 Hmgcs1 0.490 0.593
1434380_at Mm.254851 Dnr12 0.498
1455141_at Mm.218873 Tnrc6a 0.500
1448312_at Mm.294493 Pcsk2 2.012 1.729
1420575_at Mm.2064 Mt3 2.141 1.521
1428014_at Mm.158272 Hist1h4h 2.252
1449992_at Mm.207082 Isp2-pending 2.611 35.750
1430111_a_at Mm.4606 Bcat1 2.924
1418197_at Mm.4177 Ucp1 3.049 132.265
1420338_at Mm.4584 Alox15 3.067 75.309
1426039_a_at Mm.274093 Alox12e 4.464 31.213
Additional genes tested by quantitative RT-PCR
1450033_a_at Mm.277406 Stat1 0.554 0.398
1422629_s_at Mm.46014 Shrm 0.563 0.546
1451718_at Mm.1268 Plp 0.567 0.342
1427683_at Mm.290421 Egr2 0.570 0.620
1424470_a_at Mm.24028 9330170P05Rik 0.592 0.607
1450646_at Mm.140158 Cyp51 0.606 0.655
1421191_s_at Mm.142822 Gopc 0.634 0.636
1452036_a_at Mm.159684 Tmpo 0.643 0.646
1417385_at Mm.29824 Psa 0.652 0.905
1426819_at Mm.248335 Fosb 0.658 0.464
1460248_at Mm.10233 Cpxm2 0.663 0.589
1417444_at Mm.153415 E2f5 0.714 0.644
1460329_at Mm.26364 B4galt6 0.756 0.642
1448754_at Mm.279741 Rbp1 0.769 0.462
1451695_a_at Mm.332810 Gpx4 1.391 1.483
1419469_at Mm.139192 Gnb4 1.499 1.519
1424171_a_at Mm.43784 Hagh 1.543 1.499
1417111_at Mm.117294 Man1a 1.546 2.540
1417502_at Mm.18590 Tm4sf2 1.590 2.192
1422557_s_at Mm.192991 Mt1 1.645 1.554
1422586_at Mm.140765 Ecel1 1.815 2.948
1451342_at Mm.334160 Spon1 1.946 5.139
a Values are ratios of AFP KO to WT mice.
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34 selected genes also showed differential expression between
WT and AFP KO females (the only exception was the Psa
gene), thereby largely confirming the results of the microarray
analysis. It is notable that among the genes defining the AFP
KO female signature (see Table S2 in the supplemental mate-
rial), several were previously reported to be important in fe-
male fertility, on the basis of the phenotype observed in the
corresponding knockout mouse models, namely, Egr1 (28),
Cish2 (9), Ptprf (36), Psa (34), and Tkt (47).
As reported previously, AFP KO females show an anovula-
tory phenotype (21). The GnRH receptor pathway is particu-
larly important for ovulation, and this pathway is disturbed in
AFP KO females. Indeed, the GnRH receptor mRNA level is
reduced by factors of 3.5 (microarrays) to 1.7 (quantitative
RT-PCR) in the AFP KO females compared to the WT fe-
males (Table 1; see also Table S2 in the supplemental mate-
rial). Several downstream genes are also down-regulated, as
described below.
The GnRH receptor is a seven-transmembrane-domain G
protein-coupled receptor. The number of these receptor mol-
ecules varies over the estrus cycle and is thought to correlate
with the gonadotropin secretory capacity of the pituitary go-
nadotroph cells (13). It is also correlated with the level and
frequency of release (pulsatility) of its ligand, the decapeptide
GnRH produced by the hypothalamus (12, 15, 30). Binding of
GnRH to its receptor induces a rise in intracellular Ca2
concentration and activates the diacylglycerol-protein kinase C
pathway (for a review, see reference 10). This pathway directly
influences the Egr1 transcription factor that binds to the lu-
teinizing hormone beta subunit gene (Lhb) promoter, thereby
activating its transcription. When the GnRH receptor is acti-
vated, the Egr1 mRNA level increases and the activation effect
of Egr1 on the Lhb promoter is further enhanced by protein
kinase C-elicited phosphorylation (19, 42). In accordance with
a down-regulation of the GnRH receptor gene in the AFP KO
female pituitary, the Egr1 mRNA is down-regulated in these
mice (Table 1 and Fig. 1). Furthermore, Fos, the mRNA level
of which correlates with that of Egr1 (38), is also reduced
(Table 1 and Fig. 1). Interestingly, we detected that the ex-
pression level of Fosb is also down-regulated in the AFP KO
female pituitary, suggesting that both Fos and Fosb could be
regulated by Egr1. In addition, we observed differences in the
expression levels of three other genes previously described as
being part of the GnRH receptor-coupled gene network (45),
namely, transforming growth factor 1-induced transcript 4
(Tgfb1i4), protein tyrosine phosphatase 4a1 (Ptp4a1), and early
growth response 2 (Egr2) genes. The first two genes are down-
regulated in AFP KO females by a factor of 1.3 (Fig. 1; see also
Table S2 in the supplemental material), and Egr2 is down-
regulated by a factor of 1.7.
On the other hand, other hormonal secretions of the pitu-
itary represented on mouse expression set 430A showed no
differences in expression levels between WT females and AFP
KO females, namely, Gh (growth hormone), Prl (prolactin),
Fsh (follicle-stimulating hormone), and Pomc (pro-opiomela-
nocortin). Thus, differential expression of pituitary hormonal
transcripts between WT and AFP KO females seems to be
limited to the GnRH receptor pathway.
Since the GnRH receptor level is down-regulated in the
AFP KO female pituitary, and since this level is known to be
linked to the level of its ligand in a dose-dependent manner
(15), we decided to quantify the gonadotropin-releasing hor-
mone gene (Gnrh1) mRNA level in the hypothalamus (by
quantitative RT-PCR with SYBR Green dye). Gnrh1 mRNA
was found to be down-regulated by a factor of 2.5 in the AFP
KO female hypothalamus (Fig. 1) (no difference was found
between WT and AFP KO males).
Estrogen-free embryo development rescues fertility in AFP
KO females. (i) Fertility. AFP KO females are sterile either
because AFP could not play its neuroprotective role against
the effects of circulating estrogens or because AFP could not
actively bring estrogens to specific brain cells. In order to
discriminate between these two hypotheses, we injected the
aromatase inhibitor ATD to block estrogen synthesis in het-
erozygous females during the late gestational period, which is
a critical period for brain sexual differentiation. The former
hypothesis predicts that AFP KO female fetuses which develop
in an estrogen-free environment should be fertile (no estrogen,
no need for protective AFP). In contrast, the latter hypothesis
predicts that AFP KO females should be sterile (no estrogen
carrier AFP). Serum estradiol levels of the ATD-treated ges-
tating females proved the effectiveness of the treatment (es-
tradiol levels were below the 10-pg/ml detection limit of radio-
immunoassay).
Heterozygous gestating females (13 animals) were injected
with ATD, and a total of 17 AFP KO female pups and 25
heterozygous female pups were retrieved. The fertility of 8 of
the AFP KO pups and of 17 of the heterozygous pups was
FIG. 1. Schematic view of the GnRH pathway. Genes whose ex-
pression is affected in AFP KO females are indicated in bold print.
Changes in mRNA levels are shown as ratios of AFP KO to WT levels.
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tested: females of both genotypes were fertile and gave birth to
litters of normal size. Furthermore, three of these AFP KO
females and five of the heterozygous ones were then mated
again to determine whether additional litters could be obtained.
Females of both genotypes were fertile again and gave birth to
litters of normal size comprising both sterile AFP KO and
fertile heterozygous females. The correction of the sterility of
the treated AFP KO females was thus not transmitted, as
expected.
As controls, heterozygous females were injected with pro-
pylene glycol only (no ATD). They gave birth to sterile AFP
KO and fertile heterozygous females.
(ii) Gene expression. Since prenatal ATD treatment re-
stored the fertility of the AFP KO females, we then asked
whether this treatment also normalized the gene expression
level in the hypothalamic-pituitary axis of these mice. We
tested the expression of several genes in the pituitary, i.e., Ucp1
(uncoupling protein 1), Isp2 (implantation serine protease 2),
Egr1 (early growth response 1), and Gnrhr (GnRH receptor).
The results are shown in Fig. 2. Wild-type and heterozygous
animals were different from those used for microarray analysis
but were of the same backcross level as the ATD-treated and
untreated AFP KO mice. Prenatally ATD-treated AFP KO
females exhibited expression levels that were statistically dif-
ferent from those of the untreated KO females (P 0.044) but
not from those of the heterozygous, untreated females (P 
0.508), except for the Isp2 gene in which prenatally ATD-
treated KO females are statistically different from heterozy-
gous untreated females. Thus, expression of these genes
reached the levels of the fertile groups again. We then tested
Gnrh1 gene expression in the hypothalamus. Surprisingly, the
FIG. 2. Relative expression levels of genes in the pituitary (Isp2,
Ucp1, Egr1, and Gnrhr) and the hypothalamus (Gnrh1). Values are
normalized with Hprt gene values. WT, wild-type allele-homozygous
females (n  16); HET, heterozygous females (n  9); KO, homozy-
gous AFP KO females (n  7); KO ATD, prenatally ATD-treated
AFP KO females (n  7). Differences between values for KO and
ATD KO mice in the pituitary are significant (P  0.044), while
differences between values for HET and ATD KO mice are not (P 
0.508), except for Isp2 (P  0.014). For Gnrh1, WT-HET differences
are not significant, while KO-KO ATD and KO ATD-HET differences
are significant (P, 0.049 and 0.002, respectively).
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Gnrh1 expression level in the prenatally ATD-treated AFP KO
mice was not increased (Fig. 2).
DISCUSSION
We previously demonstrated that AFP is involved in female
fertility, via the activity of the hypothalamic-pituitary axis (21).
Taking into account this result, a critical property of AFP is its
capacity to bind estrogens (7, 33, 35, 44). Whether this binding
reflects a passive, neuroprotective role or a carrier activity has
remained a matter of debate (18, 41). The AFP KO mouse
allowed us to clarify this issue. Indeed, we show here that
fertility of AFP KO female mice is restored after development
in an estrogen-free environment; in other words, AFP KO
female mice are sterile as a result of prenatal overexposure to
estrogen. This result shows that AFP has a merely passive,
neuroprotective role. However, the fact that aromatase knock-
out females are sterile (20) and remain unable to ovulate even
after adult estradiol treatment (40) points out that more than
prenatal estrogen shielding of the brain alone is needed to
achieve normal female reproductive function in adulthood and
that estrogen exposure in the postnatal period is necessary for
further sexual differentiation.
We also investigated the molecular consequences of prena-
tal overexposure to estrogen (caused by the absence of embry-
onic AFP) in the developing brain. We showed that adult AFP
KO female mice suffer from anomalies in the levels of numer-
ous gene transcripts. In particular, the GnRH pathway is
down-regulated. Our results are in accordance with in vitro
studies showing that cellular differentiation and migration of
cultured GnRH cells are inhibited if the cultures are exposed
to AFP antibodies (17). The changes in gene expression de-
tected in the pituitary may well not be caused directly by
prenatal overexposure to estrogen but may be secondary to
upstream defects, having occurred in the brain and in partic-
ular in sexually dimorphic regions of the hypothalamus. In
agreement with this hypothesis, Bakker and coworkers (3)
recently showed that AFP KO females have decreased (i.e.,
male-like) numbers of tyrosine-hydroxylase-immunoreactive
cells in the anteroventricular nucleus of the preoptic region.
The fact that the GnRH pathway is stably disturbed while
the other main hormonal secretions of the pituitary are unaf-
fected is in accordance with the phenotype of the AFP KO
mice in which anovulation is the only phenotypic anomaly
detected. Correct integration of the hypothalamic GnRH surge
through its pituitary receptor is responsible for the preovula-
tory luteinizing-hormone surge and ultimately for ovulation. In
this respect, it is noticeable that Egr1 knockout females (28)
have many phenotypic similarities to AFP KO females. EGR1
is a transcription factor that binds the Lhb promoter and is
down-regulated in AFP KO female mice. Lhb mRNA levels
are not affected in female AFP KO mice, but since these mice
do not cycle properly, they could not be analyzed in the
proestrus phase of the sexual cycle in which the luteinizing-
hormone surge occurs; consequently, the Lhb mRNA levels we
measured are basal levels, which thus appear to be normal.
AFP KO male mice show no differences in Gnrh1, Gnrhr, or
Fsh gene expression, which is consistent with their normal
phenotype. Thus, the absence of embryonic AFP seems to
interfere with female brain development only.
Prenatal treatment of AFP KO female mice with an aro-
matase inhibitor not only rescues fertility but also restores the
expression profile of the tested genes in the pituitary to values
similar to those of normal, fertile heterozygous females. This
result strengthens the correlation between abnormal gene ex-
pression in the hypothalamic-pituitary axis and female fertility,
pointing to a causal relationship between the molecular anom-
alies and the phenotypic defect. However, heterozygous fe-
males, while fertile, show a GnRH receptor gene expression
level intermediate between those of WT and AFP KO females,
pointing out an AFP dose-dependent effect. Unexpectedly, in
the hypothalamus, the expression of the Gnrh1 gene remains
abnormally low, while the level of pituitary Gnrhr mRNA is
normalized. As Gnrh1 is a highly regulated gene, with tran-
scriptional and posttranscriptional regulations (for a review,
see reference 22), it is possible that stabilization of the de-
capeptide occurs, compensating for the low mRNA level.
GnRH is capable of regulating its own secretion by ultrashort
feedback mechanisms mediated by GnRH receptors present in
a subpopulation of GnRH neurons (46). On the other hand,
since pulsatility of the GnRH action is a critical feature (14),
another explanation might be that in ATD-treated AFP KO
females, even suboptimal levels of GnRH could elicit an ade-
quate pituitary response provided they are delivered in the
right pulsatile manner.
Anovulation caused by a dysfunction of the hypothalamic-
pituitary axis is frequently observed in women consulting for fer-
tility issues. Children with a congenital absence of AFP due to a
frameshift mutation in the eighth exon of the gene have been
described (37), and it will be interesting to monitor the fertility
and hormonal levels of women homozygous for the mutation.
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